• Solid 1H25 performance with revenue growth of 5% and NPATA growth of 5%
• CSL Behring delivered strong growth, with Ig up 15%, Albumin up 9%, and Idelvion up 6%
• CSL Seqirus impacted by weak seasonal markets, but pandemic tenders to partly offset
• CSL Vifor delivered 6% revenue growth, driven by iron and nephrology products

CSL reported a solid 1H25 performance, with revenue growth of 5% and NPATA growth of 5%. CSL Behring delivered strong growth, with Ig up 15%, Albumin up 9%, and Idelvion up 6%. The division also saw progress in the deployment of the Rika plasma donation system and the implementation of iNomi, which are delivering anticipated benefits. CSL Seqirus was impacted by weak seasonal markets, with a decline in the US vaccination rates and a shift in immunisation settings. However, pandemic tenders for avian influenza are expected to partly offset these challenges. CSL Vifor continued its growth trajectory, driven by iron and nephrology products, with the successful launches of Tavneos and Filspari. The company reaffirmed its FY25 guidance for revenue growth of around 5-7% and NPATA growth of around 10-13% at constant currency.

FY25 NPATA2,3 Guidance Reaffirmed: +10-13% at constant currency

CSL Behring: Underlying patient demand for Ig in core indications remains strong, momentum in HEMGENIX uptake, preparing for launch of ANDEMBRY (Garadacimab), completing RIKA roll-out, and Horizon 1 and 2 yield initiatives progressing. CSL Seqirus: Higher H5 avian influenza revenue in 2H, preparation for FLUAD launch in Germany, and Tullamarine facility proceeding to validation. CSL Vifor: Maintain leadership position in iron, continued momentum in nephrology, and geographic expansion.